Literature DB >> 20855866

Aberrant DNA hypermethylation signature in acute myeloid leukemia directed by EVI1.

Sanne Lugthart1, Maria E Figueroa, Eric Bindels, Lucy Skrabanek, Peter J M Valk, Yushan Li, Stefan Meyer, Claudia Erpelinck-Verschueren, John Greally, Bob Löwenberg, Ari Melnick, Ruud Delwel.   

Abstract

DNA methylation patterns are frequently dysregulated in cancer, although little is known of the mechanisms through which specific gene sets become aberrantly methylated. The ecotropic viral integration site 1 (EVI1) locus encodes a DNA binding zinc-finger transcription factor that is aberrantly expressed in a subset of acute myeloid leukemia (AML) patients with poor outcome. We find that the promoter DNA methylation signature of EVI1 AML blast cells differs from those of normal CD34(+) bone marrow cells and other AMLs. This signature contained 294 differentially methylated genes, of which 238 (81%) were coordinately hypermethylated. An unbiased motif analysis revealed an overrepresentation of EVI1 binding sites among these aberrantly hypermethylated loci. EVI1 was capable of binding to these promoters in 2 different EVI1-expressing cell lines, whereas no binding was observed in an EVI1-negative cell line. Furthermore, EVI1 was observed to interact with DNA methyl transferases 3A and 3B. Among the EVI1 AML cases, 2 subgroups were recognized, of which 1 contained AMLs with many more methylated genes, which was associated with significantly higher levels of EVI1 than in the cases of the other subgroup. Our data point to a role for EVI1 in directing aberrant promoter DNA methylation patterning in EVI1 AMLs.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20855866      PMCID: PMC3037746          DOI: 10.1182/blood-2010-04-281337

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  37 in total

1.  A universal framework for regulatory element discovery across all genomes and data types.

Authors:  Olivier Elemento; Noam Slonim; Saeed Tavazoie
Journal:  Mol Cell       Date:  2007-10-26       Impact factor: 17.970

2.  High EVI1 levels predict adverse outcome in acute myeloid leukemia: prevalence of EVI1 overexpression and chromosome 3q26 abnormalities underestimated.

Authors:  Sanne Lugthart; Ellen van Drunen; Yvette van Norden; Antoinette van Hoven; Claudia A J Erpelinck; Peter J M Valk; H Berna Beverloo; Bob Löwenberg; Ruud Delwel
Journal:  Blood       Date:  2008-02-13       Impact factor: 22.113

3.  TOPORS functions as a SUMO-1 E3 ligase for chromatin-modifying proteins.

Authors:  Pooja Pungaliya; Diptee Kulkarni; Hye-Jin Park; Henderson Marshall; Haiyan Zheng; Henry Lackland; Ahamed Saleem; Eric H Rubin
Journal:  J Proteome Res       Date:  2007-09-06       Impact factor: 4.466

4.  DNA methylation-dependent regulation of BORIS/CTCFL expression in ovarian cancer.

Authors:  Anna Woloszynska-Read; Smitha R James; Petra A Link; Jihnhee Yu; Kunle Odunsi; Adam R Karpf
Journal:  Cancer Immun       Date:  2007-12-21

5.  A novel interaction between the proto-oncogene Evi1 and histone methyltransferases, SUV39H1 and G9a.

Authors:  Dominik Spensberger; Ruud Delwel
Journal:  FEBS Lett       Date:  2008-07-11       Impact factor: 4.124

6.  Myeloid transforming protein Evi1 interacts with methyl-CpG binding domain protein 3 and inhibits in vitro histone deacetylation by Mbd3/Mi-2/NuRD.

Authors:  Dominik Spensberger; Michiel Vermeulen; Xavier Le Guezennec; Renee Beekman; Antoinette van Hoven; Eric Bindels; Henk Stunnenberg; Ruud Delwel
Journal:  Biochemistry       Date:  2008-05-24       Impact factor: 3.162

7.  An integrative genomic and epigenomic approach for the study of transcriptional regulation.

Authors:  Maria E Figueroa; Mark Reimers; Reid F Thompson; Kenny Ye; Yushan Li; Rebecca R Selzer; Jakob Fridriksson; Elisabeth Paietta; Peter Wiernik; Roland D Green; John M Greally; Ari Melnick
Journal:  PLoS One       Date:  2008-03-26       Impact factor: 3.240

8.  The human colon cancer methylome shows similar hypo- and hypermethylation at conserved tissue-specific CpG island shores.

Authors:  Rafael A Irizarry; Christine Ladd-Acosta; Andrew P Feinberg; Bo Wen; Zhijin Wu; Carolina Montano; Patrick Onyango; Hengmi Cui; Kevin Gabo; Michael Rongione; Maree Webster; Hong Ji; James Potash; Sarven Sabunciyan
Journal:  Nat Genet       Date:  2009-01-18       Impact factor: 38.330

9.  The UCSC Genome Browser Database: 2008 update.

Authors:  D Karolchik; R M Kuhn; R Baertsch; G P Barber; H Clawson; M Diekhans; B Giardine; R A Harte; A S Hinrichs; F Hsu; K M Kober; W Miller; J S Pedersen; A Pohl; B J Raney; B Rhead; K R Rosenbloom; K E Smith; M Stanke; A Thakkapallayil; H Trumbower; T Wang; A S Zweig; D Haussler; W J Kent
Journal:  Nucleic Acids Res       Date:  2007-12-17       Impact factor: 16.971

10.  BORIS, a paralogue of the transcription factor, CTCF, is aberrantly expressed in breast tumours.

Authors:  V D'Arcy; N Pore; F Docquier; Z K Abdullaev; I Chernukhin; G-X Kita; S Rai; M Smart; D Farrar; S Pack; V Lobanenkov; E Klenova
Journal:  Br J Cancer       Date:  2008-01-15       Impact factor: 7.640

View more
  35 in total

1.  Overexpression of Evi-1 oncoprotein represses TGF-β signaling in colorectal cancer.

Authors:  Xiyun Deng; Yanna Cao; Yan Liu; Fazhi Li; Kamalanathan Sambandam; Srinivasan Rajaraman; Archibald S Perkins; Alan P Fields; Mark R Hellmich; Courtney M Townsend; E Aubrey Thompson; Tien C Ko
Journal:  Mol Carcinog       Date:  2011-12-07       Impact factor: 4.784

2.  Mutations in DNA methyltransferase (DNMT3A) observed in acute myeloid leukemia patients disrupt processive methylation.

Authors:  Celeste Holz-Schietinger; Doug M Matje; Norbert O Reich
Journal:  J Biol Chem       Date:  2012-06-21       Impact factor: 5.157

3.  Variability in DNA methylation defines novel epigenetic subgroups of DLBCL associated with different clinical outcomes.

Authors:  Nyasha Chambwe; Matthias Kormaksson; Huimin Geng; Subhajyoti De; Franziska Michor; Nathalie A Johnson; Ryan D Morin; David W Scott; Lucy A Godley; Randy D Gascoyne; Ari Melnick; Fabien Campagne; Rita Shaknovich
Journal:  Blood       Date:  2014-01-02       Impact factor: 22.113

4.  Method to detect differentially methylated loci with case-control designs using Illumina arrays.

Authors:  Shuang Wang
Journal:  Genet Epidemiol       Date:  2011-08-04       Impact factor: 2.135

Review 5.  Analysing and interpreting DNA methylation data.

Authors:  Christoph Bock
Journal:  Nat Rev Genet       Date:  2012-10       Impact factor: 53.242

6.  Identification of differentially methylated markers among cytogenetic risk groups of acute myeloid leukemia.

Authors:  Xiaoyu Qu; Jerry Davison; Liping Du; Barry Storer; Derek L Stirewalt; Shelly Heimfeld; Elihu Estey; Frederick R Appelbaum; Min Fang
Journal:  Epigenetics       Date:  2015       Impact factor: 4.528

Review 7.  Chromatin modifiers and the promise of epigenetic therapy in acute leukemia.

Authors:  S M Greenblatt; S D Nimer
Journal:  Leukemia       Date:  2014-03-10       Impact factor: 11.528

Review 8.  Origins of aberrant DNA methylation in acute myeloid leukemia.

Authors:  T Schoofs; W E Berdel; C Müller-Tidow
Journal:  Leukemia       Date:  2013-08-20       Impact factor: 11.528

9.  Myeloid leukemia with high EVI1 expression is sensitive to 5-aza-2'-deoxycytidine by targeting miR-9.

Authors:  F Li; W He; R Geng; X Xie
Journal:  Clin Transl Oncol       Date:  2019-05-03       Impact factor: 3.405

Review 10.  The use of molecular genetics to refine prognosis in acute myeloid leukemia.

Authors:  Bhavana Bhatnagar; Ramiro Garzon
Journal:  Curr Hematol Malig Rep       Date:  2014-06       Impact factor: 3.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.